Mursla Bio Launches AI Platform for Cancer Diagnosis
Mursla Bio launched its innovative AI Precision Medicine Platform, with the vision of transforming cancer diagnosis and enhancing outcomes for high-risk patients. The platform uses advanced methods for the organ-specific isolation of EVs from blood, a quantum leap in non-invasive medical diagnosis. The firm also made available a pre-print of the first-validated protocol for the isolation of hepatocyte EVs from plasma, a quantum leap in organ-specific proteomic and miRNA profiling.
Revolutionizing Liquid Biopsy and Precision Medicine
The new platform fills a fundamental void in liquid biopsy technology by providing accurate, non-invasive access to organ-specific molecular information from blood with unprecedented spatial and biological resolution. The non-target background reduction provided by the platform's ability to harvest EVs secreted by organs into the blood significantly improves data quality and predictive model accuracy. This major achievement increases the generalization of predictive models, rendering them more useful for clinical purposes.
Also Read: VCA to Acquire HopeAI, Boosting AI in Biopharma
Key Verification and Future Directions
Mursla Bio's platform has already proven to have strong verification of hepatocyte EV isolation, verifying liver origin on the basis of proteomic and nucleic acid markers. The work, carried out with Evotec International GmbH and University College London, indicates that the technique gives consistent, organ-specific information at very low blood volume. The platform not only accelerates biomarker discovery but also facilitates AI-enabled development for a broad spectrum of disease areas, such as liver cancer. Mursla Bio's platform supports its EvoLiver™ program for surveillance of liver cancer, which has demonstrated remarkable early detection outcomes and has been designated by the FDA as a Breakthrough Device. The innovative model of the company is paving the way for the clinical adoption of precision medicine tools in the future.
